Search the Newsreel

Medpace Holdings (MEDP) EVP sells 7,500 shares of stock at $600

Medpace Holdings, Inc. EVP, Operations, Susan E. Burwig, sold 7,500 shares of common stock at $600 per share on July 28, 2026, totaling $4.5 million. The sale was executed via a limit order during an open window period, leaving her with 62,984 shares directly …

Medpace Holdings (NASDAQ: MEDP) CEO sells 7,238 shares at ~$600

Medpace Holdings CEO August J. Troendle sold 7,238 common shares in open-market transactions on July 27-28, 2026, at weighted average prices around $600 per share. These sales were executed under a limit order during an open window period and were not made under a …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to join …

Medpace Holdings Inc (MEDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Medpace Holdings Inc (MEDP), detailing its current price momentum, support and resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, KDJ, and moving averages. …

MEDP|Medpace Holdings Inc|Price:585.350|Chg%:+14.380

Medpace Holdings Inc (MEDP) closed at $585.35 on July 29, 2026, up 2.52%, with a market capitalization of $16.30 billion. The company exhibits strong fundamentals, high growth potential, and is considered fairly valued in the Biotechnology & Medical Research industry, where it ranks 65 …

Medpace Holdings, Inc. SEC Filing (Jul 28, 2026)

This SEC filing details a Form 144 for Medpace Holdings, Inc. (MEDP), indicating a proposed sale of 7,500 common shares acquired through a stock option exercise on November 19, 2024. The aggregate market value of these shares is $4,500,000.00, and they are expected to …

Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $601.09, Implies 2% Upside

Medpace Holdings, Inc.'s stock (MEDP) has seen its average 12-month price target raised to $601.09 based on estimates from 11 analysts, up from $588.91. This updated target suggests a 2% potential upside from its July 27 closing price. Despite the target increase, the consensus …

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all. In addition to volatility, these stocks carry above-average risk by …

Medpace Holdings Inc (MEDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Medpace Holdings Inc (MEDP) by business segments for the fiscal year 2025. It shows that Oncology and Metabolic segments are the largest contributors to revenue, followed by Other, Central Nervous System, Cardiology, and AVAI. The report …

Medpace Holdings, Inc. Revenue Breakdown – MIL:1MEDP

Medpace Holdings, Inc. (MIL:1MEDP) reported total revenue of ‪2.15 B‬ EUR last year, with its top-performing Oncology segment contributing ‪636.51 M‬ EUR. The majority of the company's revenue, ‪2.13 B‬ EUR, was generated in the United States. This data provides a breakdown of the …

Why Medpace Holdings (MEDP) Is Up 11.8% After Raising 2026 Guidance And Expanding Backlog

In July 2026, Medpace Holdings reported second-quarter results showing year-over-year increases in revenue and net income, and subsequently raised its 2026 guidance to forecast total revenue of US$2.81 billion–US$2.89 billion and net income of US$494 million–US$514 million, alongside updated earnings per diluted share of …

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

A strong stock as of late has been Medpace (MEDP). Shares have been marching higher, with the stock up 16.5% over the past month. The stock hit a new 52-week high of $677.9 in the previous session. Medpace has gained 7.9% since the start …

BMO raises Medpace stock price target to $600 on strong demand

BMO Capital has increased its price target for Medpace Holdings Inc. (NASDAQ:MEDP) to $600 from $400, maintaining a Market Perform rating, following Medpace's strong second-quarter results and updated 2026 guidance. Despite the target raise, the stock is currently trading above this new target at …

RBC Raises Price Target on Medpace Holdings to $692 From $484, Keeps Outperform Rating

RBC Capital Markets has increased its price target for Medpace Holdings (MEDP) to $692 from $484, while maintaining an "Outperform" rating on the stock. This adjustment comes after Medpace's recent Q2 earnings beat, revenue rise, and updated earnings guidance for 2026, which included a …

Medpace Earnings: Stronger Bookings and Easing Cancellations Support Improved Near-Term Outlook

Medpace, a narrow-moat contract research organization, is showing an improved near-term outlook. This positive change is attributed to stronger bookings and a reduction in cancellations. The company specializes in full-service drug development and clinical trial services for small and midsize biotechnology, pharmaceutical, and medical-device …

Earnings Release: Here's Why Analysts Cut Their MedPlus Health Services Limited (NSE:MEDPLUS) Price Target To ₹1,013

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

(RTTNews) - Today's top biotech gainers include Advanced Biomed, which led the rally with a gain of more than 200% over the past week. Novocure climbed following strong Q2 results and a revised full-year revenue outlook, while Medpace gained on solid quarterly performance and …

Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $508.55, Implies 4% Downside

Analyst estimates have raised the 12-month price target for Medpace Holdings, Inc. (MEDP) stock to $508.55, up from $485.36, based on 11 analysts' forecasts. This new target implies a potential 4% downside from the July 22 closing price. The consensus rating for MEDP remains …

Narrow-Moat Medpace's Stronger Bookings and Easing Cancellations Support Improved Near-Term Outlook

Medpace, a narrow-moat contract research organization, is showing an improved near-term outlook. This positive change is attributed to stronger bookings and a reduction in cancellations. The company specializes in full-service drug development and clinical trial services for small and midsize biotechnology, pharmaceutical, and medical-device …

Medpace Holdings Inc (MEDP) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Record ...

This article first appeared on GuruFocus. Revenue: $707.3 million in Q2 2026, a 17.2% year-over-year increase. Year-to-Date Revenue: $1.41 billion, up 21.7%. EBITDA: $153.4 million in Q2 2026, a 17.6% increase from Q2 2025. EBITDA Margin: 21.7% in Q2 2026, compared to 21.6% in …

Medpace Holdings, Inc. 2Q 2026: Revenue $707.33M, EPS $4.25— 10-Q Summary

Medpace Holdings, Inc. reported strong second-quarter 2026 results, with revenue increasing by 17.2% year-over-year to $707.33 million and diluted EPS rising by 37.1% to $4.25. The company's growth was driven by key services in Oncology, Metabolic, CNS, and AVAI, contributing to a substantial increase …

Medpace Holdings, Inc. SEC Filing (Jul 23, 2026)

Medpace Holdings, Inc. (MEDP) filed a Form 144 SEC notice on July 23, 2026, indicating a proposed sale of 11,000 shares of common stock with an aggregate market value of $6,950,877.79. The securities were acquired through a stock option exercise on December 6, 2024, …

MEDP Stock Jumps On Earnings Beat And Raised 2026 Outlook

Medpace Holdings Inc. (MEDP) saw its stock jump 14.71% after reporting strong Q2 2026 results, beating Street expectations for EPS and revenue, and raising its full-year 2026 guidance. Despite recent downgrades from Baird and Jefferies due to valuation concerns, Mizuho maintained an Outperform rating …

Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook

Medpace Holdings (NASDAQ:MEDP) reported strong Q2 earnings, beating consensus estimates with $4.25 EPS and $707.33 million in sales. The company's project backlog grew to over $3.01 billion, with net new business awards totaling $795.7 million. Following these results, Medpace raised its fiscal 2026 revenue …

Why Is Medpace (MEDP) Stock Soaring Today

Why Is Medpace (MEDP) Stock Soaring Today What Happened? Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) jumped 14.4% in the afternoon session after the company reported second-quarter financial results that exceeded Wall Street's expectations. GAAP earnings per share came in at $4.25, surpassing …

Medpace Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MEDP) 2026-07-23

Medpace Holdings, Inc. (MEDP) published its Q2 2026 earnings call presentation, reporting strong financial results. The company's EPS of $4.25 beat estimates by $0.25, and revenue of $707.33M represented a 17.24% year-over-year increase, surpassing expectations by $18.52M. This article provides access to the slide …

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

Medpace Holdings, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing by 17.2% to $707.3 million and net income rising to $121.4 million. The company also reported a significant increase in net new business awards, totaling $795.7 million, and …

Medpace Notches A Surprise Beat, Sending Shares Skyward

Medpace Q2 Earnings Call Highlights

This article first appeared on GuruFocus. Revenue: $707.3 million in Q2 2026, a 17.2% year-over-year increase. Year-to-Date Revenue: $1.41 billion, up 21.7%. EBITDA: $153.4 million in Q2 2026, a 17.6% increase from Q2 2025. EBITDA Margin: 21.7% in Q2 2026, compared to 21.6% in …

Medpace: 'Buy' Financial Metric Improvements And Solid Q2 2026 Earnings (NASDAQ:MEDP)

Medpace stock lifts CRO space after Q2 beat (MEDP:NASDAQ)

Medpace (MEDP) Stock Faces Margin Compression That Tests Bullish Growth Narratives

MEDP Earnings Review: Medpace Stock Soars on Bookings Beat

Medpace Holdings Stock Soars 15% After Beating Earnings Estimates And Raising Guidance

Medplus Q1FY27 revenue rises 21.8%, PAT falls 21.7%

Medpace (MEDP) Q3 2025 earnings summary

Medpace (MEDP) reported a strong Q3 2025 with revenue up 23.7% to $659.9 million, net income increasing by 15.3%, and robust net new business awards rising 47.9%. The company's backlog reached $3.0 billion, and it provided optimistic guidance for 2025 revenue and EBITDA, along …